Niemann-Pick Disease Type C Market Insight, Epidemiology and Market Forecast - 2032, Featuring Zevra Therapeutics, Azafaros, Cyclo Therapeutics and IntraBio [Yahoo! Finance]
Cyclo Therapeutics, Inc. (CYTH)
Company Research
Source: Yahoo! Finance
The report delivers an in-depth understanding of the Niemann-Pick Disease Type C, historical and forecasted epidemiology as well as the Niemann-Pick Disease Type C market trends in the United States, EU4, the United Kingdom and Japan. The report provides current treatment practices, emerging drugs, market size, market share of the individual therapies, and current and forecasted 7MM from 2019 to 2032. The report also covers current Niemann-Pick Disease Type C (NPC) treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. Key Highlights In 2022, the market size of Niemann-Pick Disease Type C (NPC) was the highest in the US among the 7MM, accounting for approximately USD 9 million, expected to increase by 2032. There are 787 diagnosed cases of Niemann-Pick Disease Type C (NPC) in the 7MM in 2022, of which 42% of patients are attributed to the US. Niemann-Pick Disease Type C (NPC) Understa
Show less
Read more
Impact Snapshot
Event Time:
CYTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTH alerts
High impacting Cyclo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CYTH
News
- Cyclo Therapeutics, Inc. (NASDAQ: CYTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.MarketBeat
- Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1 [Yahoo! Finance]Yahoo! Finance
- Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1Business Wire
- Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire
- Cyclo Therapeutics, Inc. (NASDAQ: CYTH) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $3.00 price target on the stock.MarketBeat
CYTH
Sec Filings
- 5/24/24 - Form S-3
- 5/15/24 - Form 10-Q
- 4/29/24 - Form 10-K/A
- CYTH's page on the SEC website